𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer

✍ Scribed by Emmanuel Mitry; Pascal Hammel; Gaël Deplanque; Françoise Mornex; Philippe Levy; Jean-François Seitz; Alain Moussy; Jean-Pierre Kinet; Olivier Hermine; Philippe Rougier; Eric Raymond


Publisher
Springer
Year
2010
Tongue
English
Weight
415 KB
Volume
66
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Activity of gemcitabine in patients with
✍ Malcolm Moore 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

## BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability o

Activity of gemcitabine in patients with
✍ Malcolm Moore 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

## BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability o

A pharmacological study of celecoxib and
✍ Henry Q. Xiong; William Plunkett; Robert Wolff; Min Du; Renato Lenzi; James L. A 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 223 KB

## Purpose: To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dfdctp), in peripheral blood mononuclear cells (pbmcs). ## Methods: Patients with advanced pancreatic cancer who had not received chemotherapy and had acc